balstilimab
agenus
['pancreatic', 'balstilimab']
#asco23 - head over to hall a from 8-11 a.m., where the team is presenting targeting minimal residual disease in resected ras mutated pancreatic cancer with vaccine tg01/qs-21 +/- pd-1 inhibitor, balstilimab: a randomized phase ii study (tesla). 
We are transforming cancer research and clinical care by linking our innovative approach to drug discovery, delivery and development to our patient care program